MD3171174T2 - Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer - Google Patents

Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer

Info

Publication number
MD3171174T2
MD3171174T2 MDE20170031T MDE20170031T MD3171174T2 MD 3171174 T2 MD3171174 T2 MD 3171174T2 MD E20170031 T MDE20170031 T MD E20170031T MD E20170031 T MDE20170031 T MD E20170031T MD 3171174 T2 MD3171174 T2 MD 3171174T2
Authority
MD
Moldova
Prior art keywords
prognosis
diagnosis
alzheimer
disease
lactoferin
Prior art date
Application number
MDE20170031T
Other languages
English (en)
Inventor
Diaz Eva Maria Carro
Original Assignee
Geroa Diagnostics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geroa Diagnostics S L filed Critical Geroa Diagnostics S L
Publication of MD3171174T2 publication Critical patent/MD3171174T2/ro

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79Transferrins, e.g. lactoferrins, ovotransferrins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2835Movement disorders, e.g. Parkinson, Huntington, Tourette
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Prezenta invenţie se referă la proteina lactoferinei sau la un acid nucleic care o codifică, pentru utilizare în diagnosticul sau prognosticul bolii Alzheimer (BA). Invenţia se referă la o metodă de diagnostic sau prognostic al BA la un subiect, care cuprinde evaluarea nivelului de lactoferină în salivă sau într-o probă de salivă a subiectului respectiv şi determinarea dacă nivelul menţionat este peste sau sub o valoare de 6,5 μg/ml, în care o valoare sub 6,5 μg/ml este o indicaţie a BA sau a prognosticului BA. Un alt aspect este un set care cuprinde cel puţin un reactiv, de preferinţă un anticorp, pentru cuantificarea lactoferinei în salivă sau într-o probă de salivă a unui subiect, care permite compararea cuantificării menţionate cu o valoare limită predeterminată.
MDE20170031T 2015-11-20 2015-11-20 Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer MD3171174T2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15195662.0A EP3171174B1 (en) 2015-11-20 2015-11-20 Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
MD3171174T2 true MD3171174T2 (ro) 2018-02-28

Family

ID=54697475

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20170031T MD3171174T2 (ro) 2015-11-20 2015-11-20 Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer

Country Status (29)

Country Link
US (2) US11422137B2 (ro)
EP (2) EP3171174B1 (ro)
JP (1) JP6991970B2 (ro)
KR (1) KR102579727B1 (ro)
CN (1) CN108431608B (ro)
AU (1) AU2016354981B2 (ro)
BR (1) BR112018010266A2 (ro)
CA (1) CA3005784C (ro)
CL (1) CL2018001343A1 (ro)
CO (1) CO2018006298A2 (ro)
CY (1) CY1119797T1 (ro)
DK (1) DK3171174T3 (ro)
EC (1) ECSP18046355A (ro)
ES (1) ES2657414T3 (ro)
HR (1) HRP20180115T1 (ro)
HU (1) HUE037916T2 (ro)
LT (1) LT3171174T (ro)
MD (1) MD3171174T2 (ro)
ME (1) ME02993B (ro)
MX (1) MX2018006189A (ro)
NO (1) NO3171174T3 (ro)
NZ (1) NZ743563A (ro)
PL (2) PL3171174T3 (ro)
PT (1) PT3171174T (ro)
RS (1) RS56832B1 (ro)
RU (1) RU2745602C2 (ro)
SI (1) SI3171174T1 (ro)
WO (1) WO2017085214A1 (ro)
ZA (1) ZA201804079B (ro)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201818373A2 (tr) 2018-12-03 2020-06-22 T C Erciyes Ueniversitesi Bağirsak mi̇krobi̇yomundan alzhei̇mer hastaliğinin teşhi̇si̇ i̇çi̇n mi̇ni̇mal bi̇yobeli̇rteçler ve i̇lgi̇li̇ yeni̇ nesi̇l di̇zi̇leme ki̇ti̇
CN112142850A (zh) * 2019-06-27 2020-12-29 深圳市卫光生物制品股份有限公司 人神经生长因子-乳铁蛋白重组蛋白及用途
CN111415745A (zh) * 2020-04-03 2020-07-14 河北医科大学 一种雄激素提示老年男性阿尔茨海默病风险的计算方法
CN113049696B (zh) * 2021-03-04 2022-03-18 首都医科大学宣武医院 一种诊断受试者是否患阿尔茨海默病的代谢产物及其用途
CN113967250A (zh) * 2021-09-26 2022-01-25 四川大学 乳铁蛋白在预防治疗阿尔兹海默症中的应用
CN114242175A (zh) * 2021-12-22 2022-03-25 香港中文大学深圳研究院 一种评估脑白质高信号体积的方法及系统
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
AU2002220029B2 (en) * 2000-11-14 2007-09-06 Techlab, Inc. Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
US20030096736A1 (en) 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
WO2004037073A2 (en) * 2002-10-25 2004-05-06 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel
WO2009074331A2 (en) 2007-12-11 2009-06-18 Julius-Maximilians-Universität Würzburg Early and differential diagnosis test for alzheimer's disease
US20130034863A1 (en) * 2009-01-23 2013-02-07 Philadelphia Health And Education Corporation Apparatus and Methods for Detecting Inflammation Using Quantum Dots
EP2251032A1 (en) 2009-05-12 2010-11-17 Nestec S.A. Lactoferrin and brain health and protection in adults
EP3329932A1 (en) 2009-06-10 2018-06-06 New York University Immunological targeting of pathological tau proteins
US20110236917A1 (en) 2009-11-17 2011-09-29 Power3 Medical Products, Inc. Diagnosis of Alzheimer's Disease
IN2013CN02996A (ro) * 2010-10-20 2015-08-14 Eisai R&D Man Co Ltd
WO2013014669A1 (en) * 2011-07-24 2013-01-31 Carmel-Haifa University Economic Corp. Lactoferrin fragments and use thereof
EP3255435A1 (en) 2012-04-13 2017-12-13 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
CN103575903B (zh) * 2012-08-07 2016-01-20 中国检验检疫科学研究院 一种人乳铁蛋白夹心elisa检测试剂盒及其应用

Also Published As

Publication number Publication date
EP3171174B1 (en) 2017-10-25
ZA201804079B (en) 2019-09-25
US11422137B2 (en) 2022-08-23
HRP20180115T1 (hr) 2018-04-06
JP6991970B2 (ja) 2022-01-13
HUE037916T2 (hu) 2018-09-28
RS56832B1 (sr) 2018-04-30
CY1119797T1 (el) 2018-06-27
SI3171174T1 (en) 2018-04-30
PT3171174T (pt) 2018-01-12
ES2657414T3 (es) 2018-03-05
KR20180083909A (ko) 2018-07-23
NO3171174T3 (ro) 2018-03-24
DK3171174T3 (en) 2018-01-22
WO2017085214A1 (en) 2017-05-26
EP3377909A1 (en) 2018-09-26
CL2018001343A1 (es) 2018-12-21
ME02993B (me) 2018-10-20
CA3005784A1 (en) 2017-05-26
RU2018122111A (ru) 2019-12-20
CO2018006298A2 (es) 2018-09-20
JP2018536410A (ja) 2018-12-13
BR112018010266A2 (pt) 2019-02-05
AU2016354981A1 (en) 2018-07-05
CA3005784C (en) 2023-06-13
MX2018006189A (es) 2018-09-21
CN108431608B (zh) 2021-12-07
EP3171174A1 (en) 2017-05-24
AU2016354981B2 (en) 2022-06-16
RU2018122111A3 (ro) 2019-12-20
US20230081393A1 (en) 2023-03-16
US20180328949A1 (en) 2018-11-15
KR102579727B1 (ko) 2023-09-19
ECSP18046355A (es) 2018-09-30
AU2016354981A2 (en) 2018-08-09
PL3377909T3 (pl) 2021-04-06
LT3171174T (lt) 2018-02-12
PL3171174T3 (pl) 2018-04-30
CN108431608A (zh) 2018-08-21
EP3377909B1 (en) 2020-07-22
NZ743563A (en) 2024-05-31
RU2745602C2 (ru) 2021-03-29

Similar Documents

Publication Publication Date Title
MD3171174T2 (ro) Lactoferină pentru utilizarea în diagnosticul sau prognosticul bolii Alzheimer
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
RU2016134839A (ru) Биомаркер и способы для ранней диагностики болезни альцгеймера
JP2009501333A5 (ro)
DE602007003833D1 (de) Verbesserte vitamin-d-messung
DE602006006855D1 (de) Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)
WO2014140974A3 (en) System and method for determining risk of diabetes based on biochemical marker analysis
RU2008103988A (ru) Способ диагностики рассеяного склероза
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE602007007209D1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
EP4299586A3 (en) Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
JP2017537148A5 (ro)
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
WO2015197915A3 (en) Biochemical markers for use in determining risk of diabetes
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
MX2020009705A (es) Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora.
DE602005010548D1 (de) Verbessertes verfahren zur diagnose des akuten koronarsyndroms
RU2019143570A (ru) Диагностика периодонтита на основании hgf и mmp-8 в слюне
NZ703055A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
TR201906195T4 (tr) Niemann pıck hastalığının teşhisi için metot.
WO2013119279A3 (en) Assays and methods for the diagnosis of ovarian cancer
HRP20190801T1 (hr) Biološki biljeg za rehospitalizaciju nakon srčane insuficijencije